GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
Hoffman notified Genocea Biosciences, Inc. (the Company) of his
desire to resign from the Board, effective April 11, 2017. On
April 14, 2017, Genocea Biosciences, Inc. (the Company) notified
NASDAQ that Dr. Stephen Hoffman had resigned from the Board of
Directors (the Board) of the Company effective April 11, 2017. As
a result, the Compensation Committee of the Board (the
Compensation Committee) had only one member and the Company no
longer complied with NASDAQ Listing Rule 5605(d)(2), which
requires companies with securities listed on NASDAQ to have a
compensation committee composed of at least two independent
directors. On April 14, 2017, the Board appointed Dr. Howard
Mayer to serve as a member of the Compensation Committee,
resulting in the Company being compliant with NASDAQ Listing Rule
5605(d)(2).
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
his desire to resign from the Board, effective April 11, 2017.
Dr. Hoffman has served on the Board since 2010 and has also
served as a member of the Nominating and Corporate Governance
Committee of the Board and the Compensation Committee. Dr.
Hoffmans resignation was not a result of or caused by any
disagreement with the Company.
About GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA)
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment. It has one product candidate in Phase II clinical development: GEN-003, which is a therapeutic vaccine or immunotherapy for the treatment of genital herpes infections. It has pre-clinical development programs, which include GEN-001, which is indicated for the treatment of chlamydia prophylaxis, and GEN-002, which indicated for the treatment of genital herpes prophylaxis both of which are in pre-clinical stage of development. The Company’s pipeline also includes GEN-005, which is under malaria prophylaxis, Epstein-Barr virus and immuno-oncology programs in research stage of development. GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Recent Trading Information
GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) closed its last trading session up +0.01 at 6.37 with 120,065 shares trading hands.
